Vistagen Therapeutics Inc (VTGN) Stock Price, Quote & News

Company Profile

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 577 3600

Website: www.vistagen.com

Address:

343 Allerton Avenue, South San Francisco, United States

BioBum Nov. 15 at 1:44 AM

$VTGN 5 funds probably hold like 50% of all shares

1 · Reply

mb0157 Nov. 14 at 11:08 PM

$VTGN. This is real deal.

1 · Reply

Reatavegas Nov. 14 at 10:35 PM

$VTGN 2....13G/A filed after hours

0 · Reply

Sorted_Details Nov. 14 at 6:36 PM

$VTGN The most frightening words in the 10-Q: "As of September 30, 2025, approximately $142.7 million of aggregate offering price for shares of our common stock remained available for offer and sale under the Sales Agreement"

2 · Reply

Sorted_Details Nov. 14 at 6:30 PM

$VTGN They just snuck in 33% dilution. Probably to buy some runway to compensate for the delay in Pal3. My problem beyond yet more pocket dilution is that they sold at $3/share for some cushion. They just dgaf about shareholder value. If there is a positive readout they will definitely sell more. The upside on this play slides more. Current book value is $1.37 per share y'all, and will be about $1.12 when this reads out. What do you think the price to book ratio should be on this thing right now?

2 · Reply

Haimalon Nov. 14 at 2:26 PM

$VTGN Can some explain how the cash grow from 63$ m to 77$ m although the lost money this quarter?

1 · Reply

BioBum Nov. 14 at 1:59 PM

$VTGN one thing that is really going its way, is FDA loves this company and their drugs. A non-systemic non-controlled substance just screams FDA approval. I honestly think that, even if they hit just one of these two trials, there will be still a slight chance that they moveto submit to the FDA Dr. Singh, just give us a passing trial, I don’t care if the P value barely makes it. I think we all know that this drug could benefit people, but it’s not something that will benefit a large majority.

1 · Reply

To_De_Moon Nov. 14 at 1:22 PM

$VTGN anyday now https://seekingalpha.com/news/4522029-vistagen-targets-nda-submission-for-fasedienol-in-midminus-2026-as-palisademinus-3-study?utm_source=webull.com&utm_medium=referral&feed_item_type=news

0 · Reply

bruegis283904 Nov. 14 at 12:31 PM

$VTGN "As of September 30, 2025, we had $77.2 million in cash, cash equivalents and marketable securities. We believe current cash covers all known aspects of our ongoing U.S. registration-directed PALISADE program for fasedienol for the acute treatment of SAD, including potential NDA submission if our PALISADE program is successful. "

0 · Reply

queensjo Nov. 14 at 7:22 AM

$VTGN Take a lesson from Musk... Talk about developing a spray-on treatment for Alzheimer's disease, just like Tesla's stock is being pumped up with words.

0 · Reply

Vistagen Therapeutics, Inc. (VTGN) Q2 2026 Earnings Call Transcript

Nov 13, 2025, 4:30 PM EST - 1 day ago

Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update

Nov 10, 2025, 8:30 AM EST - 4 days ago

Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025

Nov 5, 2025, 8:30 AM EST - 9 days ago

Vistagen to Participate in Stifel Healthcare Conference 2025

Nov 3, 2025, 8:30 AM EST - 11 days ago

Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder

Oct 29, 2025, 8:30 AM EDT - 16 days ago

Vistagen Appoints Paul Edick to its Board of Directors

Oct 16, 2025, 8:30 AM EDT - 4 weeks ago

Vistagen to Present at The Menopause Society 2025 Annual Meeting

Sep 9, 2025, 8:30 AM EDT - 2 months ago

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Aug 8, 2025, 2:13 PM EDT - 3 months ago

Vistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call Transcript

Aug 7, 2025, 4:30 PM EDT - 3 months ago

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

Jul 31, 2025, 8:30 AM EDT - 3 months ago

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

Jul 24, 2025, 8:30 AM EDT - 4 months ago

Vistagen to Present at the BTIG Virtual Biotechnology Conference

Jul 15, 2025, 8:30 AM EDT - 4 months ago

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

Jun 25, 2025, 8:30 AM EDT - 5 months ago

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

Jun 17, 2025, 6:49 PM EDT - 5 months ago

Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript

Jun 17, 2025, 4:30 PM EDT - 5 months ago

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Jun 12, 2025, 8:30 AM EDT - 5 months ago

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

Jun 2, 2025, 8:30 AM EDT - 5 months ago

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

May 28, 2025, 8:30 AM EDT - 6 months ago

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

May 23, 2025, 8:30 AM EDT - 6 months ago

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

Apr 17, 2025, 8:30 AM EDT - 7 months ago

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

Mar 19, 2025, 8:30 AM EDT - 8 months ago

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

Mar 4, 2025, 8:30 AM EST - 9 months ago

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Feb 20, 2025, 8:30 AM EST - 9 months ago

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

Feb 14, 2025, 6:19 PM EST - 9 months ago

Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication

Feb 13, 2025, 8:47 PM EST - 9 months ago

Vistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call Transcript

Feb 13, 2025, 4:30 PM EST - 9 months ago

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

Feb 6, 2025, 8:30 AM EST - 10 months ago

Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

Feb 5, 2025, 8:30 AM EST - 10 months ago

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

Jan 14, 2025, 8:30 AM EST - 10 months ago

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

Jan 10, 2025, 8:30 AM EST - 11 months ago

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

Nov 14, 2024, 8:30 AM EST - 1 year ago

Vistagen to Present at the Stifel 2024 Healthcare Conference

Nov 10, 2024, 7:43 AM EST - 1 year ago

Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript

Nov 7, 2024, 4:20 PM EST - 1 year ago

Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

Nov 5, 2024, 8:30 AM EST - 1 year ago

Vistagen to Present at the 2024 Neuroscience Education Institute Congress

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024

Oct 15, 2024, 7:25 AM EDT - 1 year ago

Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder

Oct 9, 2024, 8:30 AM EDT - 1 year ago

Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day

Sep 23, 2024, 8:30 AM EDT - 1 year ago

Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Aug 13, 2024, 7:05 PM EDT - 1 year ago

Vistagen Therapeutics, Inc. (VTGN) Q1 2025 Earnings Call Transcript

Aug 13, 2024, 4:21 PM EDT - 1 year ago

Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update

Aug 6, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024

Jul 9, 2024, 8:30 AM EDT - 1 year ago

Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine

Jun 27, 2024, 8:30 AM EDT - 1 year ago

Vistagen Awarded Mental Health America's Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year

Jun 11, 2024, 6:41 PM EDT - 1 year ago

Vistagen Therapeutics, Inc. (VTGN) Q4 2024 Earnings Call Transcript

Jun 11, 2024, 4:20 PM EDT - 1 year ago

Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Jun 7, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024

May 29, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Present at the Jefferies Global Healthcare Conference

May 23, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference

May 7, 2024, 8:30 AM EDT - 1 year ago

Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference

BioBum Nov. 15 at 1:44 AM

$VTGN 5 funds probably hold like 50% of all shares

1 · Reply

mb0157 Nov. 14 at 11:08 PM

$VTGN. This is real deal.

1 · Reply

Reatavegas Nov. 14 at 10:35 PM

$VTGN 2....13G/A filed after hours

0 · Reply

Sorted_Details Nov. 14 at 6:36 PM

2 · Reply

Sorted_Details Nov. 14 at 6:30 PM

2 · Reply

Haimalon Nov. 14 at 2:26 PM

$VTGN Can some explain how the cash grow from 63$ m to 77$ m although the lost money this quarter?

1 · Reply

BioBum Nov. 14 at 1:59 PM

1 · Reply

To_De_Moon Nov. 14 at 1:22 PM

0 · Reply

bruegis283904 Nov. 14 at 12:31 PM

0 · Reply

queensjo Nov. 14 at 7:22 AM

$VTGN Take a lesson from Musk... Talk about developing a spray-on treatment for Alzheimer's disease, just like Tesla's stock is being pumped up with words.

0 · Reply

Stmkr Nov. 14 at 4:40 AM

$VTGN Will this stay at just$110M market towards ph3 readout? Or have a $KALA like move towards the readout. With a positive prior study I expect this to run further towards the readout

0 · Reply

veargogan Nov. 13 at 11:53 PM

$VTGN Does anyone have a connection for acquiring analyst reports. If so, please message me. Thanks.

0 · Reply

mikesterz7 Nov. 13 at 11:05 PM

$VTGN Clinical Trials: VistaGen is progressing its late-stage clinical programs, particularly the Phase 3 trials for fasedienol (a treatment for social anxiety disorder). The company anticipates top-line data from its PALISADE-3 trial in Q4 2025 and the PALISADE-4 trial in the first half of 2026. Financial Position: As of September 30, 2025, the company had $77.2 million in cash, cash equivalents, and marketable securities to support ongoing research and development efforts. Prior Quarter (Q1 FY26): In the previous quarter, VistaGen reported an EPS of -$0.47, which was in line with analyst estimates, and a revenue of $0.24 million, which beat estimates.

0 · Reply

Don_Wick Nov. 13 at 10:24 PM

$VTGN Beat revenue. Missed EPS.. no price change

2 · Reply

TheGlassesFella Nov. 13 at 10:18 PM

$VTGN I saw some bullshit comments about this stock. I mean, every one of us we are here for the exact same reason and we all know that Vistagen doesn't have solid fundamentals and it's a high risk investment. As soon as I know if they passed the 3rd FDA phase, I'll be out . Just control your risk and set an important point to get out in case the results are positive or negative. Good luck to all of us.

0 · Reply

d_risk Nov. 13 at 10:00 PM

$VTGN - Vistagen Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors VTGN’s latest 10-Q risk factors spotlight tougher neuropsychiatric drug development due to subjective efficacy measures, major hurdles in market adoption and commercialization, expanded product liability and cyber risks, new challenges from remote work, intensified competition for talent, and heightened regulatory and political uncertainty—while streamlining or removing prior details on manufacturing, reimbursement, and global compliance. #NeuropsychiatricDrugs #RegulatoryUncertainty #TalentCompetition #RemoteWorkImpact #CybersecurityRisks #ProductLiability #MarketAdoptionChallenges #DrugDevelopmentRisks 🟢 Added 🟠 Removed https://d-risk.ai/VTGN/10-Q/2025-11-13

0 · Reply

Haimalon Nov. 13 at 9:12 PM

$VTGN What time they release the earnings?

0 · Reply

pops132005 Nov. 13 at 8:14 PM

$VTGN earnings drop will hopefully be the last one till data release

0 · Reply

MoffaMan Nov. 13 at 7:17 PM

$VTGN This stock is falling fastest then my girlfriends prom dress on prom night lol

2 · Reply

veargogan Nov. 13 at 5:54 PM

$VTGN I will note as I always have since the beginning of these trials that the one flaw in the trial design is giving the participants only three minutes to prepare for a five minute speech unless that "speech" is fairly rudimentary and more about the conveyance of information than a speech that is persuasive in nature requiring the use of advocacy skills. And if about the conveyance of information, are they allowed to use notes or an outline and things of that nature. I speak from the perspective of a trial attorney and a clinical professor who teaches how to litigate and handle trial work. The single most important thing and the key to minimizing the sudden appearance of anxiety is meticulous preparation as that will allow someone to communicate in a genuine way, otherwise you sound contrived and the looks from a confused panel of people can send you into a panic I've even posed that question during a quarterly meeting but was outbid by a non-shareholding analyst.

2 · Reply

veargogan Nov. 13 at 5:27 PM

$VTGN Anyone remember the 2021 SA article below that had this to predict: "the author projects VistaGen Therapeutics, Inc. as a "buy" at a 5-8 year price target of $101 (+4,206% upside)." It's now almost five years later and I know I've been here with some of you since 2021. Can't believe how much has happened in the world and in our personal lives while we waited for this company to conduct just a few public speaking experiments. I believe the article's prediction of a $100 target is realistic if PH94B passes the trials, is approved, and is indeed as effective as it claims to be as that will open up so many label and off-label uses that it's revenue will readily reach billions worldwide and ramp up from there. All of this does not even account for the pipeline drugs. Singh it to me baby! https://seekingalpha.com/article/4400577-vistagen-patience-could-lead-to-significant-upside

3 · Reply

gramirez Nov. 13 at 5:08 PM

bad days? perfect for improve my AVG in $VTGN !!

0 · Reply

Market Cap	116.58M
Revenue (ttm)	490,000.00
Net Income (ttm)	-51.42M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-10,493.88%
Debt to Equity Ratio	0.00

Volume	307,000
Avg Vol	522,088
Day's Range	N/A - N/A
Shares Out	30.68M
Stochastic %K	29%
Beta	0.56
Analysts	Strong Sell
Price Target	$13.00